31 Antibody

What is IL-31 and why is it significant in immunological research?

IL-31 is a 24 kDa short-chain member of the alpha-helical family of cytokines, primarily produced by activated T cells, particularly Th2 cells, as well as mast cells, macrophages, and dendritic cells. It signals through a heterodimeric receptor complex composed of IL-31 receptor A (IL-31RA, also called GPL) and oncostatin M receptor beta (OSM Rβ). IL-31 is particularly significant in immunological research because it mediates cell-mediated immunity against pathogens and plays crucial roles in inflammatory skin conditions, especially those associated with pruritus (itching) . The cytokine has been directly linked to the development of pruritus in humans, making it a key target for therapeutic intervention in dermatological disorders such as atopic dermatitis .

How does IL-31 signaling work at the molecular level?

IL-31 signaling begins when the cytokine binds directly to IL-31RA (GPL) within the heterodimeric receptor complex. While IL-31 directly binds to GPL, it does not directly interact with OSM R. After binding, the receptor complex activates multiple downstream signaling pathways, including:

• Janus kinase/Signal Transducer and Activator of Transcription (Jak/STAT) pathway

• Phosphatidylinositol 3-kinase (PI3K)/AKT cascade

• Mitogen-activated protein kinase (MAPK) pathway

These signaling cascades ultimately lead to altered gene expression profiles that promote inflammatory responses and pruritus. Of note, only the full-length isoform of IL-31RA containing the complete cytoplasmic domain is capable of signal transduction, despite the existence of multiple isoforms .

What types of IL-31 antibodies are available for research purposes?

Several types of IL-31 antibodies are available for research applications:

Each antibody type has specific applications depending on research requirements, with monoclonals offering higher specificity and polyclonals providing broader epitope recognition .

What are the optimal conditions for detecting IL-31 in human samples?

Detection of IL-31 in human samples requires careful consideration of sample preparation, antibody selection, and detection methods. For peripheral blood mononuclear cells (PBMCs), optimal detection has been achieved with the following protocol:

• Sample preparation: Immersion fixation of PBMCs after stimulation with calcium ionomycin and PMA

• Primary antibody: Goat Anti-Human IL-31 Antigen Affinity-purified Polyclonal Antibody (15 μg/mL)

• Incubation: 3 hours at room temperature

• Secondary detection: Fluorescent-conjugated anti-goat IgG secondary antibody

• Counterstaining: DAPI for nuclear visualization

This protocol permits visualization of IL-31 localized to both cell surfaces and cytoplasm. When working with serum or plasma samples, monoclonal antibodies such as MT31/88 have shown excellent specificity when used as capture antibodies in sandwich immunoassays, particularly when paired with biotinylated detection antibodies like MT158 .

How should IL-31 antibodies be stored to maintain optimal activity?

Storage conditions significantly impact antibody performance. Based on experimental data with various IL-31 antibodies, the following storage recommendations maximize stability and activity:

• Long-term storage: -20°C to -70°C for periods up to 12 months from receipt

• Medium-term storage (1 month): 2-8°C under sterile conditions after reconstitution

• Repeated use storage (up to 6 months): -20°C to -70°C under sterile conditions after reconstitution

Critical considerations include:

• Using manual defrost freezers to prevent temperature fluctuations

• Avoiding repeated freeze-thaw cycles which significantly reduce antibody activity

• Storing reconstituted antibodies in small aliquots to minimize freeze-thaw exposure

• Maintaining sterile conditions for reconstituted antibodies to prevent microbial contamination

What controls should be included when designing experiments with IL-31 antibodies?

Robust experimental design with IL-31 antibodies requires several controls to ensure valid and interpretable results:

• Isotype controls: Include appropriate isotype-matched control antibodies (e.g., IgG1 for mouse monoclonal antibodies) to control for non-specific binding

• Positive controls: Use cell lines known to express IL-31 or recombinant IL-31 protein

• Negative controls: Include IL-31-negative samples or cell lines

• Blocking controls: Pre-incubate samples with recombinant IL-31 to demonstrate binding specificity

• Secondary antibody controls: Include conditions with secondary antibody only to assess background

• Dosage validation: Test multiple antibody concentrations to determine optimal working dilutions (e.g., the efficacy of 15 μg/mL for IL-31 detection in PBMCs has been experimentally verified)

Implementing these controls ensures reliable interpretation of results and helps distinguish specific IL-31 signals from background or non-specific binding.

How can IL-31 receptor antagonists be designed and validated?

The development of effective IL-31 receptor antagonists requires strategic design and rigorous validation. One successful approach involved creating a fusion protein (OSMR-L-GPL) consisting of external portions of OSMR and GPL connected by a linker sequence. This 720-amino acid fusion protein effectively neutralizes IL-31 activity by:

• Competitive binding: The fusion protein competes with membrane-bound receptors for IL-31

• Pathway inhibition: It blocks downstream signaling through both STAT and MAPK pathways

• Cell-specific neutralization: Shows efficacy in multiple IL-31-sensitive cell lines, including brain-derived cells and primary keratinocytes

Validation of such antagonists should include:

• Binding assays to confirm interaction with IL-31

• Cell-based phosphorylation assays to demonstrate inhibition of downstream signaling

• Functional assays in relevant cell types to show biological neutralization

• Dose-response studies to determine IC50 values

• Specificity testing against related cytokines to ensure selective inhibition

What methodologies are most effective for studying IL-31 involvement in pruritus?

Investigating IL-31's role in pruritus requires multifaceted approaches spanning molecular, cellular, and clinical methodologies:

• Molecular techniques:

  • Quantitative PCR to measure IL-31 and receptor expression in tissues

  • RNA sequencing to identify transcriptional changes in response to IL-31 signaling

  • Protein interaction studies to map downstream effectors

• Cellular approaches:

  • Calcium imaging to measure neuronal activation in response to IL-31

  • Co-cultures of immune cells and sensory neurons to study intercellular communication

  • Patch-clamp electrophysiology to record neuronal firing patterns

• In vivo models:

  • Transgenic mice overexpressing IL-31 to study chronic pruritus

  • Behavioral assessment of scratching behaviors in response to IL-31 administration

  • Testing of IL-31 receptor antagonists for anti-pruritic effects

• Clinical investigations:

  • Assessment of pruritus using validated scales (e.g., visual analogue scale)

  • Sleep efficiency measurements to determine indirect effects of pruritus reduction

  • Biomarker analysis in patient samples

These integrated approaches have been successfully employed to demonstrate IL-31's direct involvement in pruritus and validate therapeutic strategies targeting this pathway.

What are the key considerations for developing therapeutic IL-31 receptor antibodies?

Development of therapeutic anti-IL-31 receptor antibodies requires careful consideration of multiple factors:

• Antibody engineering:

  • Humanization to minimize immunogenicity (e.g., CIM331/nemolizumab)

  • Affinity optimization for maximal receptor blockade

  • Selection of appropriate IgG subclass for desired effector functions

• Pharmacokinetic considerations:

  • Half-life optimization for appropriate dosing intervals

  • Tissue distribution analysis to ensure target engagement

  • Route of administration (subcutaneous delivery has shown efficacy)

• Safety assessment:

  • Rigorous toxicology studies across multiple dose levels

  • Monitoring for immune-related adverse events

  • Assessment of potential immunogenicity

  • Evaluation for unexpected effects on related signaling pathways

• Efficacy endpoints:

  • Primary: Reduction in pruritus scores (visual analogue scale)

  • Secondary: Improvement in sleep efficiency

  • Tertiary: Reduction in concomitant medication use (e.g., topical corticosteroids)

  • Biomarkers: Changes in inflammatory mediators

Clinical trials with CIM331 have demonstrated promising results with a single subcutaneous dose reducing pruritus by approximately 50% at week 4, compared to 20% reduction with placebo, without significant adverse events or dose-dependent toxicity .

What strategies can address poor IL-31 detection in immunoassays?

When facing challenges with IL-31 detection in immunoassays, researchers should systematically troubleshoot:

• Sample preparation issues:

  • Ensure proper cell stimulation (e.g., using calcium ionomycin and PMA for PBMCs)

  • Optimize fixation methods (immersion fixation has shown good results)

  • Consider protein extraction methods that preserve cytokine integrity

• Antibody selection and optimization:

  • Verify antibody specificity using recombinant IL-31

  • Optimize antibody concentration (15 μg/mL has been validated for certain applications)

  • Test multiple antibody clones or polyclonal preparations

• Detection system refinement:

  • Evaluate secondary antibody quality and specificity

  • Optimize signal amplification methods

  • Consider more sensitive detection systems for low abundance samples

• Protocol modifications:

  • Extend incubation times (3 hours at room temperature has proven effective)

  • Adjust blocking conditions to reduce background

  • Optimize wash steps to improve signal-to-noise ratio

When working with clinical samples, consider that IL-31 may be present in complexes with soluble receptors or other binding proteins that could mask epitopes, necessitating additional sample processing steps.

How can researchers address non-specific binding in IL-31 antibody applications?

Non-specific binding can significantly compromise results in IL-31 antibody applications. Effective mitigation strategies include:

• Optimized blocking protocols:

  • Use species-appropriate serum or protein blockers

  • Consider specialized blocking reagents for problematic tissues

  • Implement extended blocking periods for high-background samples

• Antibody validation and selection:

  • Perform pre-adsorption tests with recombinant IL-31

  • Compare multiple antibody clones for specificity profiles

  • Use affinity-purified antibodies rather than crude preparations

• Washing optimization:

  • Increase washing frequency and duration

  • Add mild detergents to wash buffers (e.g., 0.05% Tween-20)

  • Consider specialized washing protocols for different sample types

• Control implementation:

  • Include isotype-matched control antibodies

  • Perform peptide competition assays to verify specificity

  • Include gradient titration of primary antibodies to identify optimal concentrations

For immunoprecipitation experiments specifically, researchers should employ overnight incubation at 4°C with antibodies to maximize specific binding while minimizing non-specific interactions .

What emerging applications exist for IL-31 antibodies beyond dermatological research?

While IL-31 has been predominantly studied in dermatological contexts, emerging research indicates broader applications:

• Respiratory research:

  • Investigation of IL-31's role in asthma and allergic airway inflammation

  • Studies on sensorineural mechanisms of cough involving IL-31 signaling

  • Exploration of IL-31 in pulmonary fibrosis pathogenesis

• Gastrointestinal applications:

  • Research on IL-31 in intestinal inflammation and motility

  • Investigation of visceral hypersensitivity mechanisms

  • Studies on gut-brain axis signaling involving IL-31

• Neuroimmunology:

  • Exploration of IL-31's role in neuroimmune communication

  • Studies on neurogenic inflammation mechanisms

  • Investigation of IL-31 in neuropathic itch and pain

• Oncology applications:

  • Research on IL-31's potential role in tumor microenvironments

  • Studies on cancer-associated pruritus mechanisms

  • Investigation of IL-31 signaling in hematological malignancies

These expanding research areas highlight the need for specialized antibodies and detection systems optimized for diverse tissue types and experimental conditions.

How might combination therapies involving IL-31 antibodies enhance therapeutic outcomes?

Strategic combination approaches involving IL-31 antibodies could potentially enhance therapeutic efficacy:

• Multi-cytokine targeting approaches:

  • Combined blockade of IL-31 and IL-4/IL-13 (Th2 cytokines)

  • Dual inhibition of IL-31 and IL-17 pathways for mixed inflammatory phenotypes

  • Targeting IL-31 alongside TSLP for comprehensive pruritus management

• Pathway-specific combinations:

  • IL-31 receptor blockade combined with JAK inhibitors for enhanced downstream inhibition

  • Targeting both IL-31 and neuronal sensitization pathways (e.g., TRPV1 antagonists)

  • Combining IL-31 antibodies with barrier repair agents for comprehensive dermatitis management

• Diagnostic-therapeutic combinations:

  • Development of companion diagnostics to identify high IL-31 expressors

  • Biomarker-guided combination therapy selection

  • Personalized approaches based on cytokine profiling

• Novel delivery strategies:

  • Topical delivery systems for localized IL-31 antibody application

  • Sustained-release formulations for extended therapeutic effect

  • Targeted delivery to specific tissue compartments

Early clinical findings with CIM331 suggest that IL-31 receptor blockade alone provides significant symptomatic relief, but combination approaches may address multiple disease mechanisms simultaneously for enhanced outcomes.